Defining the survival benchmark for breast cancer patients with systemic relapse

Simon B. Zeichner, Tadeu Ambros, John Zaravinos, Alberto J. Montero, Reshma L. Mahtani, Eugene R. Ahn, Aruna Mani, Nathan J. Markward, Charles L. Vogel

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


BACKGROUND:Our original paper, published in 1992, reported a median overall survival after first relapse in breast cancer of 26 months. The current retrospective review concentrates more specifically on patients with first systemic relapse, recognizing that subsets of patients with local recurrence are potentially curable. METHODS:Records of 5,168 patients from a largely breast-cancer-specific oncology practice were reviewed to identify breast cancer patients with their first relapse between 1996 and 2006 after primary treatment. There were 189 patients diagnosed with metastatic disease within 2 months of being seen by our therapeutic team and 101 patients diagnosed with metastatic disease greater than 2 months. The patients were divided in order to account for lead-time bias than could potentially confound the analysis of the latter 101 patients. RESULTS:Median survival for our primary study population of 189 patients was 33 months. As expected, the median survival from first systemic relapse (MSFSR) for the 101 patients excluded because of the potential for lead-time bias was better at 46 months. Factors influencing prognosis included estrogen receptor (ER) status, disease-free interval (DFI), and dominant site of metastasis. Compared with our original series, even with elimination of localregional recurrences in our present series, the median survival from first relapse has improved by 7 months over the past two decades. CONCLUSION:The new benchmark for MSFSR approaches 3 years.

Original languageEnglish (US)
Pages (from-to)9-17
Number of pages9
JournalBreast Cancer: Basic and Clinical Research
StatePublished - Feb 12 2015


  • Breast cancer
  • Disease-free interval
  • Estrogen receptor positive
  • HER2 positive
  • Median survival
  • Metastatic breast cancer
  • Systemic relapse

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Defining the survival benchmark for breast cancer patients with systemic relapse'. Together they form a unique fingerprint.

Cite this